Physician profile
Marcus K Weldon
NPI 1942689286
$12,633.53
in general payments reported to CMS, 2019-2025
63 companies · $2,216 in 2025
The $2,216 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2021: $1,046 · 2022: $2,616 · 2023: $3,376 · 2024: $3,124 · 2025: $2,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,710 · Long Term Medical Supply Or Device Loan: $682 · Education: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,710.40 |
| Long Term Medical Supply Or Device Loan | $681.53 |
| Education | $324.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,198.25 | 2021-2025 | |
| Pfizer INC. | $739.64 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $636.39 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Regeneron Healthcare Solutions, INC. | $631.51 | 2022-2025 | Libtayo |
| Seagen INC. | $621.34 | 2021-2025 | Padcev, Tukysa, Adcetris |
| Incyte Corporation | $556.33 | 2019-2025 | Jakafi, Niktimvo, Monjuvi |
| Amgen INC. | $541.85 | 2019-2023 | Kyprolis, Vectibix, Xgeva |
| Astellas Pharma US INC | $503.28 | 2021-2025 | Xtandi, Padcev, Vyloy |
| Abbvie INC. | $434.88 | 2022-2025 | Venclexta |
| Daiichi Sankyo INC. | $430.96 | 2022-2025 | Injectafer, Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $379.41 | 2021-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Pharmacyclics LLC, An Abbvie Company | $340.75 | 2021-2023 | Imbruvica |
| Exelixis INC. | $338.91 | 2021-2025 | Cabometyx |
| Genzyme Corporation | $312.83 | 2021-2025 | |
| Celgene Corporation | $309.63 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $278.94 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Gilead Sciences, INC. | $270.73 | 2022-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $265.29 | 2021-2025 | |
| Eisai INC. | $264.64 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $240.43 | 2022-2024 | Calquence, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $236.23 | 2022-2025 | Darzalex, Tecvayli, Erleada |
| Genentech USA, INC. | $229.18 | 2022-2025 | Polivy, Tecentriq, Rozlytrek |
| E.R. Squibb & Sons, L.L.C. | $223.50 | 2021-2025 | Opdualag, Opdivo |
| Jazz Pharmaceuticals INC. | $179.39 | 2023-2025 | Zepzelca |
| Stemline Therapeutics INC. | $136.60 | 2023-2025 | Elzonris, Orserdu |
| Beone Medicines USA, INC. | $134.26 | 2025 | Brukinsa, Tevimbra |
| Aveo Pharmaceuticals, INC. | $127.95 | 2022-2025 | Fotivda |
| Alexion Pharmaceuticals, INC. | $119.54 | 2021-2025 | Ultomiris |
| Beigene USA, INC. | $110.62 | 2022-2024 | Brukinsa |
| Servier Pharmaceuticals LLC | $110.22 | 2021-2024 | |
| Karyopharm Therapeutics INC. | $109.77 | 2022-2024 | Xpovio |
| Lilly USA, LLC | $89.72 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Ipsen Biopharmaceuticals, INC | $89.37 | 2021-2025 | Onivyde, Tazverik |
| Adaptive Biotechnologies Corporation | $88.09 | 2022-2024 | Clonoseq |
| Deciphera Pharmaceuticals INC. | $84.36 | 2021-2025 | Qinlock, Tgct |
| Sun Pharmaceutical Industries INC. | $79.64 | 2022-2024 | Odomzo, Yonsa |
| Array Biopharma INC | $76.82 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Mirati Therapeutics, INC. | $72.20 | 2023-2024 | Krazati |
| Puma Biotechnology, INC. | $67.81 | 2023-2025 | Nerlynx |
| Abiomed | $63.36 | 2024 | Impella |
| Pharmaessentia USA Corporation | $59.85 | 2025 | Besremi |
| Tersera Therapeutics LLC | $57.33 | 2022-2025 | Zoladex |
| Medtronic, INC. | $57.16 | 2024-2025 | Osteocool Rf Ablation System |
| Foundation Medicine, INC. | $56.28 | 2022 | |
| Kite Pharma, INC. | $55.90 | 2023 | Yescarta |
| Sobi, INC | $54.05 | 2023-2025 | |
| Coherus Oncology, INC. | $46.83 | 2021-2024 | |
| Geron Corporation | $46.55 | 2024-2025 | Rytelo |
| Syndax Pharmaceuticals, INC. | $44.89 | 2025 | |
| Myriad Genetic Laboratories, INC. | $44.58 | 2023 | Mychoice Cdx, Precisetumor |
| Rigel Pharmaceuticals, INC. | $44.50 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Acrotech Biopharma INC. | $43.31 | 2022-2024 | Beleodaq |
| Blueprint Medicines Corporation | $41.34 | 2021-2022 | |
| Epizyme, INC. | $36.86 | 2021-2022 | |
| Morphosys, US INC. | $32.92 | 2021-2024 | Monjuvi |
| Adc Therapeutics America, INC. | $30.13 | 2022-2024 | |
| Pharmaand Gmbh | $29.41 | 2025 | Rubraca |
| Tolmar, INC. | $29.41 | 2025 | Eligard, Rubraca |
| Immunogen, INC. | $26.81 | 2024 | Elahere |
| Taiho Oncology, INC. | $23.00 | 2021 | |
| Springworks Therapeutics, INC. | $20.22 | 2025 | Ogsiveo |
| Clovis Oncology, INC. | $15.33 | 2021 | |
| Acceleron Pharma, INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Weldon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.